Henry Schulte
Psychiatry · Scottsdale, AZNPI 1114061553
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $66,858 of the $77,268 with a category attached, or 86.5%. AbbVie accounts for 74.9% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2019 at $29,843 and has fallen 87.4% since, to $3,756 in 2025. Among psychiatry clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 656 payments — averaging $117.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$58K
- Otsuka America Pharmaceutical, Inc.$9K
- Brainsway USA Inc$4K
- Sunovion Pharmaceuticals Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$903
- Takeda Pharmaceuticals U.S.A., Inc.$569
- plus $4K from 22 others
What the payments were for
- Speaking & faculty fees$66,85887%
- Travel & lodging$4391%
- Food & beverage$9,57812%
- Education$3931%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 261 | $57,896 |
| Otsuka America Pharmaceutical, Inc. | 84 | $8,662 |
| Brainsway USA Inc | 5 | $4,413 |
| Sunovion Pharmaceuticals Inc. | 48 | $1,237 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 52 | $903 |
| Takeda Pharmaceuticals U.S.A., Inc. | 42 | $569 |
| Teva Pharmaceuticals USA, Inc. | 21 | $543 |
| Vanda Pharmaceuticals Inc. | 22 | $502 |
| Alkermes, Inc. | 21 | $427 |
| Lundbeck LLC | 23 | $421 |
| Corium, LLC | 21 | $413 |
| Axsome Therapeutics, Inc. | 12 | $285 |
| Johnson & Johnson | 8 | $187 |
| Idorsia Pharmaceuticals US Inc | 5 | $96 |
| Neurocrine Biosciences, Inc. | 4 | $95 |
| Noven Therapeutics, LLC | 4 | $87 |
| Bausch Health US, LLC | 4 | $87 |
| Shire North American Group Inc | 4 | $78 |
| Janssen Scientific Affairs, LLC | 1 | $72 |
| Eisai Inc. | 3 | $64 |
| Almatica Pharma LLC | 3 | $63 |
| Alfasigma USA, Inc. | 2 | $44 |
| Tris Pharma Inc | 1 | $23 |
| Ironshore Pharmaceuticals Inc. | 1 | $22 |
| OWP Pharmaceuticals, Inc. | 1 | $21 |
| Neuronetics, Inc. | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$54,778
- REXULTI$7,316
- Brainsway Deep TMS$4,282
- LATUDA$885
How this compares
$77,268 in reported general payments places this provider in the 95th percentile of 573 psychiatry providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 28 | $54,238 |
| TrintellixVortioxetine Hydrobromide | 32 | $34,503 |
| BelsomraSuvorexant | 21 | $15,060 |
| Lurasidone Hcl | 14 | $7,794 |
| CymbaltaDuloxetine Hcl | 25 | $6,709 |
| Dextroamphetamine Sulfate | 27 | $6,666 |
| Paxil CrParoxetine Hcl | 12 | $5,895 |
| Venlafaxine Hcl | 18 | $3,300 |
| Escitalopram Oxalate | 285 | $2,996 |
| Triazolam | 31 | $2,824 |
| Quetiapine Fumarate | 119 | $2,673 |
| Paliperidone ErPaliperidone | 15 | $2,357 |
| Eszopiclone | 62 | $2,126 |
| Sertraline Hcl | 152 | $2,083 |
| Aripiprazole | 146 | $2,052 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $57,896 | $54,23828 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $569 | $34,50332 claims |
| Almatica Pharma LLCSertraline Hcl | $63 | $2,083152 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 573 psychiatry providers in Arizona.
Other psychiatry in Scottsdale
- Lauren BonnerScottsdale$44K
- Lois KrahnScottsdale$32K
- Alvin BursteinScottsdale$18K
- Marie GronleyScottsdale$8K
- Alpa SanghviScottsdale$6K
- Adam KoelschScottsdale$5K
- Elizabeth RotellaScottsdale$4K
- Supriya NairScottsdale$4K
- Paul ValbuenaScottsdale$4K
- Jason CaplanPhoenix$999K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.